Streetbeat News

Regulatory

SPY

Fed's Bowman indicated that as inflation declines, the Federal Reserve will need to lower interest rates. The focus will be on how subcategories of inflation evolve.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:03 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has announced that it is prioritizing the development of EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders without hallucinogenic effects. The company is advancing pre-clinical development and targeting a pre-IND meeting with the FDA for early 2025.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:03 pm

BABA

BIDU

MSFT

TCEHY

OpenAI, backed by Microsoft, plans to restrict access to its AI tools in China starting in July. This move aligns with U.S. efforts to limit China's access to advanced AI technology. Chinese tech giants like Alibaba and Tencent-backed Zhipu AI are urging developers to switch to their products.

Portfolio Pulse from Benzinga Neuro

June 25, 2024 | 11:55 am

BTCUSD

The upcoming presidential debate between Joe Biden and Donald Trump is unlikely to significantly impact Bitcoin's price, according to analysts from Bitfinex. However, tokens like Maga Coin (TRUMP) and JEO BODEN (BODEN) could see volatility. Polymarket sets the odds of Trump mentioning cryptocurrencies at 46%.

Portfolio Pulse from Aniket Verma

June 25, 2024 | 11:46 am

CARM

Carisma Therapeutics shares are trading higher after the FDA granted Fast Track Designation for CT-0525 to treat HER2-overexpressing solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:39 am

NVEI

Nuvei Corporation has secured approval for a Retail Services Category II License from the Central Bank of the UAE, allowing it to expand into the United Arab Emirates and strengthen its presence in the Middle East and North Africa.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:37 am

WVE

Wave Life Sciences announced positive results from its Phase 1B/2A SELECT-HD trial of WVE-003 for Huntington's Disease, showing a 46% reduction in mutant huntingtin protein with preservation of wild-type huntingtin. The company plans to engage regulators for potential accelerated approval and submit an opt-in package to partner Takeda. The data validate Wave's RNA medicines platform and pipeline.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:35 am

CCL

FDX

NVDA

PRGS

QQQ

RIVN

SPY

WOR

U.S. stocks are set for a mixed session with tech stocks, particularly Nvidia, poised for a rebound. Nvidia is up over 2% in premarket trading. The market is also focused on upcoming speeches by Federal Reserve officials and a consumer confidence reading. The first presidential debate on Thursday could significantly impact market sentiment.

Portfolio Pulse from Shanthi Rexaline

June 25, 2024 | 11:34 am

CARM

Carisma Therapeutics announced that the FDA has granted Fast Track Designation for its drug candidate CT-0525, aimed at treating HER2-overexpressing solid tumors. Initial Phase 1 data is expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:32 am

UNCY

Unicycive Therapeutics announced favorable results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal trial, highlighting its tolerability and safety. The company plans to submit a New Drug Application in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:32 am